The Next Generation of Vaccines and Immunotherapies

Site Map | Copyright | Home

 

Product Overview

Virionics is focused on the development of vaccines and immunotherapies against diseases where no effective vaccines or immunotherapies exist.

Clinical and/or research data from MediGene AG, National Institutes of Health (NIH) and our other collaborators indicate that our licensed virus-like particle (VLP) technology is extremely effective in preventing and treating a broad range of chronic diseases and provides effective protection against a wide variety of acute life-threatening diseases. VLPs can be used to prevent disease, treat existing disease, and to generate human immune globulins that can be used to treat disease.

The product pipeline table below lists our VLP programs and their stage of clinical development:

Product Pipeline

Product
Pre-Clinical
Phase I
Phase II
Phase III
PapViRx™
HPV related CIN II/III Therapy
           
HepCVax™
Chronic HCV Prevention
           
HepCiRx™
Acute HCV Therapy
           
CIgImmune™
for Liver Transplantation
           
RetroVax™
VLP + AVAXIN™-CCR5
           

 

 
 

Product Overview
Virus-Like Particles (VLPs)
PapviRx for HPV
HepCVax for HCV
RetroVax for HIV